Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 4/20 | 0.56 |
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 0.56 |
| ▸ | SLC6A3 known ✓ | Q01959 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6099403 | 1.00 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5905511 | 0.99 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3353601 | 0.99 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7255955 | 0.99 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3862732 | 0.99 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13127870 | 0.87 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8783095 | 0.85 | MEN1 (0.49) | — | |
| SCHEMBL2877536 | 0.85 | SLC6A2 (0.74) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9137609 | 0.85 | MEN1 (0.49) | — | |
| SCHEMBL2877540 | 0.85 | SLC6A2 (0.74) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220370-A1 | Preparation of 4-(4-fluorophenyl)-N-alkylnipecotinate esters, 4-(4-fluorophenyl)-N-arylnipecotinate esters and 4-(4-fluorophenyl)-N-aralkylnipecotinate esters | APOTEX PHARMACHEM INC (CA) | 2003-11-27 | — | — | US | claimed |
| WO-2003097599-A1 | PREPARATION OF 4-(4-FLUOROPHENYL)-N-SUBSTITUTEDNIPECOTINATE ESTERS | APOTEX PHARMACHEM INC. (CA) | 2003-11-27 | — | — | WO | claimed |
| US-7138523-B2 | Preparation of 4-(4-fluorophenyl)-N-alkylnipecotinate esters, 4-(4-fluorophenyl)-N-arylnipecotinate esters and 4-(4-fluorophenyl)-N-aralkylnipecotinate esters | APOTEX PHARMACHEM INC. (CA) | 2006-11-21 | — | — | US | disclosed |
| US-20030220370-A1 | Preparation of 4-(4-fluorophenyl)-N-alkylnipecotinate esters, 4-(4-fluorophenyl)-N-arylnipecotinate esters and 4-(4-fluorophenyl)-N-aralkylnipecotinate esters | APOTEX PHARMACHEM INC (CA) | 2003-11-27 | — | — | US | disclosed |
| WO-2003097599-A1 | PREPARATION OF 4-(4-FLUOROPHENYL)-N-SUBSTITUTEDNIPECOTINATE ESTERS | APOTEX PHARMACHEM INC. (CA) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220370-A1 | Preparation of 4-(4-fluorophenyl)-N-alkylnipecotinate esters, 4-(4-fluorophenyl)-N-arylnipecotinate esters and 4-(4-fluorophenyl)-N-aralkylnipecotinate esters | PFAS, B3GNT2, APRT | SLC6A2 2456/4885SLC6A4 594/4885SLC6A3 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.